---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005116"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:47:20.376028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent

## Summary
- Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.
- Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.
- Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.
- ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.
- R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend.

## SEC filing metadata
- accession: 0001171843-25-005116
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/0001171843-25-005116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/f8k_080625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005116
- JSON: https://secwatch.observer/filing/0001171843-25-005116.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.